Published Data from the NIH A study published by the National Institutes of Health (NIH) found that patients who took Semaglutide experienced a weight loss percentage of 6.6% after three months and 13.3% after six months
Reddy's Laboratories on April 28, 2026 (the first approval, making Canada the first G7 country to clear a generic) and Apotex's Apo-Semaglutide Injection on May 1, 2026 (the first Canadian-made generic)
Whether you're struggling with obesity, insulin resistance, persistent hunger, weight regain, or metabolic health concerns, our experienced providers create individualized treatment plans designed to help you achieve lasting results
The glycosuria induced by these medications creates a glucose-rich urinary environment that can promote genital mycotic infections (thrush) in 1015% of patients, particularly women
The individual on-the-go stick packs are super convenient, and while Liquid I.V